. Ponjee et al., Clin. Chem., "One-Step Chromogenic Equiva lent of Activated Partial Thromboplastin Time Evaluated for Clinical Application", 37/7, 1235 Application", 37/7, -1244 Application", 37/7, (1991 The present invention concerns a method and a reagent for the determination of the activated partial thromboplastin time (APTT) in a one-step reaction. The method and reagent according to the invention are particularly suitable for determinations in which APTT is carried out together with determinations of other parameters of the blood coagulation system.
The determination of the activated partial thromboplastin time (APTT) is one of the measurements that are carried out most frequently in coagulation analytics. It mainly serves to detect factor deficiencies in the plasma of patients such as a lack of decrease in factor VIII and to monitor heparin therapy.
The analysis is usually carried out as follows: a sample of the patient's plasma is admixed with an activator. Factor XII is activated during an incubation phase. Subsequently the reaction is started with calcium chloride. The time period until the sample clots is measured.
Reagents for carrying out this method have already been known for along time and are distributed for example by the Baxter, Ortho and DiaMed Companies. Kaolin, silicate or ellagic acid are usually used as the activator.
The actual measurement is carried out by manual inver sion of the analytical tubes and visual observation of throm bus formation. However, the clotting time can also be determined using optical or mechanical measurement instru ments such as those that are marketed by the Amelung, Baxter, Labor and Behring Companies.
However, the conventional method described above has some significant drawbacks:
1. The activation phase must be assumed to be constant for all patients so that specific characteristics of the patients cannot be taken into account in the measurement. However, activation of the endogenous coagulation system and fibrin olysis that is also important for the haemorrhagic and thrombogenic tendency of the patient starts during this activation phase. Thus an incubation period that is too short leads to increased times, even in normal plasma, because activation is incomplete. The values also increase when the incubation periods are too long because the activated fibrin olytic system releases cleavage products from fibrinogen that retard coagulation.
2. A second disadvantage of the conventional method is that the analysis has to be carried out in two steps which increases the possibility of errors and makes it more difficult to standardize the determination methods.
3. Furthermore the fact that a current APTT determination is on the whole difficult to standardize is an important disadvantage of the existing method. The measurement results are usually determined in seconds, however, varia tions are inevitable in the production of the reagent since the activators are not exactly defined chemical substances that always have the same surface. In addition it is difficult to obtain the phospholipids necessary for the clotting process in a chemically pure form and to keep their activity constant. Other important coagulation tests such as thromboplastin time (PT) and fibrinogen are rapid reaction processes that can be carried out using a single test reagent, a two-step test with a relatively long preincu bation period does not fit in well with the analytical pro cesses when for example several parameters of the coagul lation system are to be determined in parallel and substantially decreases the analytical throughput.
5. Furthermore it is desirable to start the reaction with plasma since this would considerably simplify the test procedure, calculation and analyzer functions.
The underlying technical problem of the present invention was therefore to avoid the disadvantages of the state of the art to as large an extent as possible i.e., in particular to enable an inclusion of the activation phase in the APTT reaction, a standardization of the results, a decrease in the number of pipetting steps and to allow the reaction to be started with the sample liquid, in particular plasma.
This problem was solved by a method for the determina tion of activated partial thromboplastin time (APTT) in a one-step reaction which is characterized in that the deter mination of APTT is started by contacting a reagent that contains the substances necessary for the APTT determina tion in a premixed form with a sample liquid.
In the method according to the invention the reagent can be placed in a vessel for the determination and then the reaction can be started by the addition of the sample liquid. On the other hand it is also possible to add the sample liquid first and start the reaction by addition of the premixed reagent. It is important that the determination is started by the direct contact of reagent and sample liquid without the activation phase necessary in the methods of the prior art being required.
The determination of APTT according to the method of the invention is preferably carried out by using blood or plasma that is diluted, if desired, particularly preferably by using plasma as the sample liquid.
The reagent for the determination of APTT contains the substances necessary for the determination of APTT in a premixed form. The necessary substances are usually an activator component, divalent cations and phospholipids. Kaolin, silicate orlandellagic acid are preferably used as the activator. The concentrations of the activator are for example preferably 25 to 250 mg/1, particularly preferably 100 to 100 mg/l glass-wool-activated elagic acid per liter reagent. The phospholipids contained in the reagent can be obtained from animal or/and vegetable tissue extracts or/and can be pro duced synthetically. Chloroform extracts from rabbit brain are an example of suitable phospholipids. The extract pref erably from 0.2 to 1.0 g and particularly preferably from 0.4 to 0.6 g rabbit brain is used per liter reagent. The divalent cations present in the reagent are preferably calcium ions that are for example provided by adding calcium chloride to the reagent. The concentration of calcium ions in the ana lytical solution is preferably 5 to 15 mmol/l, particularly preferably 7.5 to 12.5 mmol/1.
In addition it is preferred that the reagent is stabilized by one or several amino acids. The shelf life of the reagent even at higher temperatures (e.g., 37 C.) is considerably increased by this stabilization. Amino acids that are selected from the group comprising D-alanine, L-alanine, 3-alanine, glycine and valine are preferably used for the stabilization. Moreover it is preferred that the amino acids are present at a total concentration of 0.5 to 10% in relation to the total weight of the reagent.
5,506,146 3 It was surprisingly found that, contrary to all previous test instructions, it is possible to determine APTT in a one-step test procedure. Thus the activator and the phospholipids can be mixed with the divalent cations (e.g., calcium chloride) and this mixture can if desired be stabilized with amino acids (e.g., alanine). A premixed reagent is obtained in this way which contains all substances necessary to determine the APTT. It is now possible to start the reaction by directly contacting the sample liquid e.g., plasma with this reagent. Surprisingly the activation phase which was previously considered to be absolutely necessary can be omitted in the method according to the invention.
In a preferred embodiment of the method according to the invention the reagent is already packaged in vessels, in particular cuvettes. The reagent can be in a liquid or solid form e.g., as a solution or as a lyophilisate. The vessels are preferably made of an impervious transparent material such as e.g., polypropylene.
Moreover it is preferred that the vessels are sealed air and water-tight after dispensing the reagent. In order to achieve this a closure is for example used that consists of an aluminum foil seal. In this way it is possible to significantly simplify the determination of APTT and to integrate it into analytical systems for determining other parameters of the coagulation system by industrially packaging or pre-filling the vessels with the APTT reagents.
For this purpose it is additionally preferred that several vessels are integrated into one card i.e., in a common holder. Reagent-or/and batch-specific data can be stored on this holder or/and on the vessels themselves. Such a storage can for example be in the form of a bar code label.
In this manner batch-specific correction factors for the reagent can be used which significantly facilitate the stan dardization of results and thus their interpretation. Moreover the reagent components do not have to be pipetted in the laboratory which represents an optimization of the test and enables a great simplification of the computer program for controlling the analytical process and evaluating the results, in particular when the measuring vessels are industrially packaged or pre-filled e.g., when the measuring vessels are composed of an impervious material such as polypropylene and are hermetically sealed with a foil or cap.
The invention of the one-step test for determining APTT as described above also enables patient profiles to be pre pared in a simple manner by for example additionally integrating the reagents for measuring thromboplastin time, fibrinogen, thrombin time and reptilase time into one reagent combination e.g., a card consisting of several vessels. It is also possible to adapt further coagulation tests such as coagulation factors (e.g., factors VIII, IX, X, XI, XII), protein S and protein C. In order to carry out the test it is only necessary to start the reaction with the patient's plasma.
All test-specific information such as normal values, calibra tion curves etc. can be stored on a bar code and it is thus no longer necessary to provide a fresh normal plasma pool (FNP), a source of much error, and to establish calibration curves in the user's laboratory. When the analysis is carried out automatically, it is also not necessary to pipette reagents and the complicated logistic for this is superfluous. A combination of coded reagents with coded patient samples eliminates mistakes and thus leads to optimal, reliable results.
Thus a further object of the present invention is the combination of the method of determining APTT with further determination methods that can be carried out par allel to the APTT determination. Examples of this are further The invention also concerns a reagent for the determina tion of the activated partial thromboplastin time (APTT) in a one-step reaction which contains all the substances nec essary for the determination of APTT in a premixed form. Such a reagent usually contains phospholipids, an activator and divalent cations as specified above. The reagent is preferably stabilized by one or several amino acids as specified above. The reagent according to the invention differs from reagents of the prior art in that it contains all substances necessary for the APTT determination in a pre mixed form whereas in the case of the known reagents for the determination of APTT at least one essential component, usually the divalent ions, was lacking.
The reagent is preferably packaged or pre-filled in a vessel in a liquid or solid form (e.g., as a powder or lyophilisate) and can comprise several vessels integrated into one card and reagent-orland batch-specific data can be The described invention is elucidated in more detail by the following examples. EXAMPLE 1 50 ml APTT reagent (DiaCelin, DiaMed) is mixed with ml 0.02 mol/l calcium chloride. 0.2 ml of this mixture is pipetted into cuvettes of the Labor Company. The reaction is started with 0.1 ml plasma. The coagulation time-course is monitored optically and recorded in an analyzer from the Labor Company (Coascreener). Normal plasma, abnormal plasma (average and high), heparin plasma (0.15 u/ml and 0.3 u/ml), factor-deficient plasma samples (factor VIII, IX, X, XI, XII, content ca. 1%) are used as the plasma samples. Parallel to this the plasma samples are analysed in a con ventional manner according to the instructions using the reagents from the DiaMed Company. The results are sum marized in Table 1 normal plasma 1 (NP) abnormal plasma 1 (AP1) abnormal plasma 2 (AP2) heparin plasma 1 (HP1) heparin plasma 2 (HP2) factor-deficient plasma VIII factor-deficient plasma IX factor-deficient plasma X factor-deficient plasma XI The experiment according to example 1 is repeated with the addition of amounts of amino acids as stated in each case in order to improve the stability. The degree of stabilization at various concentrations is determined with normal plasma in a stress test by storing the reagent at 37°C. The results are summarized in Table 2 The experiment according to example 1 is repeated, however, the thromboplastin time (PT), fibrinogen (Fib), thrombin time (TT) and reptilase time (RT) are also deter mined simultaneously. Reagents from the DiaMed Company are used. The reagents are used as follows: a) DiaPlastin for measuring the thromboplastin time (PT) 0.2 ml of the reagent is pipetted into the first cuvette. The reaction is started with 0.1 ml plasma. b) DiaCelin for measuring the activated partial thrombo plastin time (APTT) 0.2 ml of the reagent -prepared as in example 1-is pipetted into the second cuvette. The reaction is started with 0.1 ml plasma. c) Fibrinogen reagent for the determination of the fibrino gen concentration
The thrombin reagent is mixed 1+1 with Owren buffer, 0.2 ml thereof is pipetted into the third cuvette. The reaction is started with 0.02 ml plasma.
d) DiaThrombin for the determination of the thrombin time (TT).
The lyophilisate is dissolved in 31 ml distilled water, 0.2 ml thereof is pipetted into the fourth cuvette. The reaction is started with 0.2 ml plasma. e) DiaReptin for the determination of the reptilase time (RT) 0.1 ml of the reagent is diluted with 3 ml distilled water. 0.2 ml of the dilution is piperred into the fifth cuvette. The reaction is started with 0.2 ml plasma.
The results of example 3 are summarized in The experiment according to example 3 is repeated. 20 selected from the group consisting of D-alanine, L-alanine, However, the reagents are previously dispensed into cuvettes made of polypropylene and are sealed tight with an aluminum foil. The results are summarized in Table 4 . It turns out that pre-dispensing and sealing the reagents does not alter the results. I claim: 9. The method of claim 1, wherein the reagentis packaged 1. A method for the determination of the activated partial thromboplastin time (APTT) in a one-step reaction compris ing. a) providing a reagent that contains an activator, phos pholipids and divalent cations in a premixed form, b) contacting a sample liquid with the reagent of step a), and c) measuring the time course of coagulation. 2. The method of claim 1, wherein plasma is used as the sample liquid.
